US12194049B2 - Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection - Google Patents
Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection Download PDFInfo
- Publication number
- US12194049B2 US12194049B2 US17/436,296 US202017436296A US12194049B2 US 12194049 B2 US12194049 B2 US 12194049B2 US 202017436296 A US202017436296 A US 202017436296A US 12194049 B2 US12194049 B2 US 12194049B2
- Authority
- US
- United States
- Prior art keywords
- sulbactam
- ceftazidime
- acinetobacter baumannii
- composition
- resistant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 241000588626 Acinetobacter baumannii Species 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 title claims abstract description 38
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 28
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 20
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims abstract description 141
- 229960005256 sulbactam Drugs 0.000 claims abstract description 137
- 229960000484 ceftazidime Drugs 0.000 claims abstract description 101
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims abstract 19
- 238000000034 method Methods 0.000 claims description 24
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 21
- 229960002260 meropenem Drugs 0.000 claims description 19
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 14
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 14
- 229960002182 imipenem Drugs 0.000 claims description 14
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 claims description 6
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 claims description 6
- 229960003169 biapenem Drugs 0.000 claims description 6
- 229960000895 doripenem Drugs 0.000 claims description 6
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 229950011346 panipenem Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 43
- 229940079593 drug Drugs 0.000 abstract description 40
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 97
- 230000000845 anti-microbial effect Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 230000000813 microbial effect Effects 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229930186147 Cephalosporin Natural products 0.000 description 7
- 229940124587 cephalosporin Drugs 0.000 description 7
- 150000001780 cephalosporins Chemical class 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- 230000003641 microbiacidal effect Effects 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 5
- 229960004682 cefoperazone Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940126575 aminoglycoside Drugs 0.000 description 3
- 229940043312 ampicillin / sulbactam Drugs 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- NWOYIVRVSJDTLK-YSDBFZIDSA-L disodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylate Chemical compound [Na+].[Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 NWOYIVRVSJDTLK-YSDBFZIDSA-L 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008261 resistance mechanism Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940041007 third-generation cephalosporins Drugs 0.000 description 3
- 229960004089 tigecycline Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 108020004256 Beta-lactamase Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940041011 carbapenems Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 2
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- -1 1-carboxy-1-methylethoxy Chemical group 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- KGWHMDCQVDMTNZ-UHFFFAOYSA-N 2-(butylcarbamoylamino)acetic acid Chemical compound CCCCNC(=O)NCC(O)=O KGWHMDCQVDMTNZ-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 206010067182 Bronchial wall thickening Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 108010068385 carbapenemase Proteins 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960003547 ceftazidime pentahydrate Drugs 0.000 description 1
- JEEWDSDYUSEQML-ROMZVAKDSA-M ceftazidime sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C([O-])=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 JEEWDSDYUSEQML-ROMZVAKDSA-M 0.000 description 1
- 229960002940 ceftazidime sodium Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940041006 first-generation cephalosporins Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000020235 metallo-beta-lactamase Human genes 0.000 description 1
- 108060004734 metallo-beta-lactamase Proteins 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940041008 second-generation cephalosporins Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960000614 sulbactam sodium Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the field of medicine, and in particular to a method and a composition for treating diseases caused by Acinetobacter baumannii infections, especially by carbapenem antibiotic-resistant Acinetobacter baumannii infections.
- Acinetobacter baumannii is a non-fermenting Gram-negative bacterium and is an important pathogen. It is widely recognized that Acinetobacter baumannii is an important cause of serious infections. Clinically, serious infections in systems such as respiratory, blood, abdominal cavity, central nervous system, urinary and skin soft tissues are closely related to Acinetobacter baumannii.
- Xiangxin L I et al. (Chinese Journal of Antibiotics, 2007, 32(12): 762-764) retrospectively investigated the clinical distribution of clinically isolated Acinetobacter baumannii from January 2002 to December 2006, and found that among 865 strains of Acinetobacter baumannii isolated within the 5 years, 75.7% were mainly derived from respiratory tract specimens. Chengdong S U N et al.
- a variety of antimicrobial drugs have varying degrees of antimicrobial activities against Acinetobacter baumannii , and each has its own advantages and disadvantages. Examples include antibiotics of cephalosporins, quinolones, sulbactam and sulbactam-containing compound preparations, carbapenems, colistins, glycylcyclines, and aminoglycoside, etc. Among them, colistins have the best antimicrobial effect against Acinetobacter baumannii ; however, the tolerance is relatively poor. The hepatic and renal toxicity of glycylcyclines, aminoglycosides etc. is relatively high. Quinolones have a disabling risk. High adverse reactions often limit the clinical application of drugs.
- Cephalosporins have a relatively good safety.
- the third-generation cephalosporin, ceftazidime has a relatively good antimicrobial effect on Gram-negative bacteria, especially possessing the best effect against Pseudomonas aeruginosa ; however, its antimicrobial effect on Acinetobacter baumannii is moderate.
- Sulbactam also has a relatively good safety; however, sulbactam has always been used as a ⁇ -lactamase inhibitor in combination with other ⁇ -lactam antibiotics to improve the antimicrobial activity of the antibiotics, and representative sulbactam-containing compound preparations include ampicillin/sulbactam, cefoperazone/sulbactam etc.; furthermore, sulbactam itself has only a moderate degree of activity against Acinetobacter baumannii .
- Carbapenem antibiotics such as imipenem, meropenem, panipenem, biapenem and doripenem, are very stable against ⁇ -lactamases and have strong antimicrobial effects, among which imipenem and meropenem are representatives; however, they are not as safe as cephalosporins and are strictly controlled in clinical use.
- Xiangxin L I et al. found that the resistance of Acinetobacter baumannii clinically isolated from January 2002 to December 2006 to commonly used antimicrobial drugs increased year by year; Chengdong S U N et al. as mentioned above found that the resistance rate of Acinetobacter baumannii clinically isolated from the inpatients in Beijing Jishuitan Hospital from January 2009 to December 2012 to cefotaxime, piperacillin, meropenem, imipenem, ciprofloxacin, tetracycline etc. could be up to 100%; and Yili L I U et al.
- Acinetobacter baumannii had a resistance rate of up to 72% to ceftazidime, up to 62.1% to ampicillin/sulbactam, up to 66.7% to imipenem, up to 69.3% to meropenem, and up to 43.5% to cefoperazone/sulbactam. According to the ranking of top 12 drug-resistant bacteria published by the World Health Organization in 2017, Acinetobacter baumannii was ranked No. 1 in the term of severe drug resistance level.
- Sulbactam-related preparations have attracted attention in the treatment of drug-resistant Acinetobacter baumannii infections due to the better safety.
- Sulbactam itself has a relatively high MIC value for Acinetobacter baumannii and a limited antimicrobial effect.
- the synergistic effect of sulbactam-containing compound preparations on drug-resistant Acinetobacter baumannii has been studied.
- Hua T A N et al. (Chinese Journal of Antibiotics, 2006, 31(8): 488-491) studied the effect of sulbactam combinations on cephalosporin-resistant Acinetobacter baumannii , wherein clinically isolated 56 strains of Acinetobacter baumannii resistant or intermediate to cefoperazone (CPZ), ceftazidime (CAZ) or cefotaxime (CTX) were divided into three groups: Group A was resistant to two or more of the above-mentioned drugs, Group B was resistant to CPZ only, and Group C was intermediate to CPZ or CTX.
- CPZ cefoperazone
- CAZ ceftazidime
- CTX cefotaxime
- MICs minimal inhibitory concentrations
- Menglan ZHOU et al. (Chinese Journal of Clinical Laboratory Science, 2018, 36(1): 22-24) selected 23 strains of clinically meropenem-resistant Acinetobacter baumannii and 21 strains of meropenem-susceptible Acinetobacter baumannii , carried out a combined drug susceptibility test by the checkerboard dilution method, and calculated the fractional inhibitory concentration index (FIC) to determine the effect of combinations (synergy, partial synergy, irrelevance or antagonism).
- FIC fractional inhibitory concentration index
- cephalosporins combined with sulbactam did not show a synergistic effect, while cefoperazone combined with sulbactam mainly showed an additive effect (43.5%), and ceftazidime combined with sulbactam mainly showed an irrelevant effect (52.2%).
- the resistance mechanisms of bacteria are quite complicated, and there are differences among different bacteria.
- the resistance mechanisms of Acinetobacter baumannii mainly include: (1) production of enzymes which inactivate antimicrobial drugs, including: 1) (3-lactamases: TEM-type and SHY-type enzymes of class A, metallo- ⁇ -lactamases of class B, AmpC-type enzymes of class C, OXA-type enzymes of class D, etc.; and 2) aminoglycoside modifying enzymes; (2) changes in target sites of drug action: topoisomerases, 16S rRNA methylase gene mutations, etc.; and (3) decrease in the amount of drugs reaching the target sites of action, including a decrease in the permeability of outer membrane porin and the overexpression of efflux pumps.
- Acinetobacter baumannii The genome of Acinetobacter baumannii has shown that it is rich in efflux pump genes, and the high expression of efflux pumps plays an important role in the multi-drug resistance of Acinetobacter baumannii . (Qiuping L I U et al., Chinese Journal of Antibiotics, 2018, 43(10): 1179-1187)
- the resistance of Acinetobacter baumannii to cephalosporins is mainly due to the production of large amounts of AmpC cephalosporinases. Since carbapenem antibiotics are highly stable against AmpC-type enzymes, clinically, carbapenem antibiotics are generally used for the treatment of cephalosporin-resistant Acinetobacter baumannii infection. However, for carbapenem-resistant Acinetobacter baumannii , the resistance mechanism is different, which is mainly attributed to production of OXA-type carbapenemases, in addition, down-regulation of membrane channel protein expression, over-expression of drug efflux pump, etc. also play important roles. Therefore, for Acinetobacter baumannii infections with different drug resistances, targeted treatment is required. However, for carbapenem antibiotic-resistant Acinetobacter baumannii infections, effective antibiotic compositions are lacking currently.
- An object of the present invention is to provide the use of a composition of sulbactam and ceftazidime in the preparation of a medicament for treating the infection with carbapenem antibiotic-resistant Acinetobacter baumannii.
- Another object of the present invention is to provide a method for treating the infection with carbapenem antibiotic-resistant Acinetobacter baumannii.
- a further object of the present invention is to provide a composition of sulbactam and ceftazidime for treating the infection with carbapenem antibiotic-resistant Acinetobacter baumannii.
- composition of sulbactam and ceftazidime in the preparation of a medicament for treating the infection with carbapenem antibiotic-resistant Acinetobacter baumannii , wherein the amount of ceftazidime in the sulbactam and ceftazidime composition is 10%-90% by mass of the amount of sulbactam.
- the amount of ceftazidime in the sulbactam and ceftazidime composition is 20%-80% of the amount of sulbactam.
- the amount of ceftazidime in the sulbactam and ceftazidime composition is 20%-40% of the amount of sulbactam.
- the amount of ceftazidime in the sulbactam and ceftazidime composition is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the amount of sulbactam.
- the carbapenem antibiotic is at least one of meropenem, imipenem, panipenem, biapenem or doripenem.
- the carbapenem antibiotic-resistant Acinetobacter baumannii is also resistant to ceftazidime.
- the sulbactam and ceftazidime composition is a non-oral preparation.
- the sulbactam and ceftazidime composition is an injection or an inhalant.
- sulbactam and ceftazidime in the sulbactam and ceftazidime composition may be individually packaged (that is, the two are packaged separately and then combined), or may also be mixed packaged (that is, the two are mixed and then packaged).
- the two may be used in the form of a compound preparation after being mixed, or may also be used in combination in the form of single preparations.
- the daily dose of sulbactam in the sulbactam and ceftazidime composition is 2 g-20 g. It can be administered 2 to 4 times a day in divided doses.
- the daily dose of ceftazidime in the sulbactam and ceftazidime composition is 0.2 g-18 g. It can be administered 2 to 4 times a day in divided doses.
- a method for treating the infection with carbapenem antibiotic-resistant Acinetobacter baumannii comprising administering to a patient therapeutically effective amounts of sulbactam and ceftazidime, wherein the amount of ceftazidime is 10%-90%, 20%-80% or 20%-40% by mass of the amount of sulbactam.
- the amount of ceftazidime is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the amount of sulbactam.
- the carbapenem antibiotic-resistant Acinetobacter baumannii is resistant to at least one carbapenem antibiotic of meropenem, imipenem, panipenem, biapenem or doripenem.
- Acinetobacter baumannii is also resistant to ceftazidime.
- sulbactam and ceftazidime are used in the form of a compound preparation.
- sulbactam and ceftazidime are used in combination in the form of single preparations.
- the administration route is non-oral administration, preferably injection administration or inhalation administration.
- the dose of administration may be adjusted according to the clinical severity of the disease.
- the daily dose of sulbactam may be 2 g-20 g
- the daily dose of ceftazidime may be 0.2 g-18 g. It can be administered 2 to 4 times a day in divided doses.
- a composition of sulbactam and ceftazidime for treating the carbapenem antibiotic-resistant Acinetobacter baumannii infection is provided, wherein the amount of ceftazidime in the sulbactam and ceftazidime composition is 10%-90%, 20%-80% or 20%-40% by mass of the amount of sulbactam.
- the carbapenem antibiotic-resistant Acinetobacter baumannii is resistant to at least one carbapenem antibiotic of meropenem, imipenem, panipenem, biapenem or doripenem.
- Acinetobacter baumannii is also resistant to ceftazidime.
- sulbactam and ceftazidime are packaged individually or in a mixed manner.
- the sulbactam and ceftazidime composition is a non-oral preparation. Furthermore, it is an injection or an inhalant.
- the sulbactam and ceftazidime composition can unexpectedly effectively treat the infections with carbapenem antibiotic-resistant Acinetobacter baumannii , and the therapeutic effect is even superior than that of a composition of carbapenem antibiotics and sulbactam.
- FIG. 1 shows the in vitro cumulative microbial inhibition rate of combinations of sulbactam and low-proportion ceftazidime against carbapenem antibiotic-resistant Acinetobacter baumannii.
- FIG. 2 shows the in vitro long-term microbicidal effects of combinations of sulbactam and low-proportion ceftazidime against carbapenem antibiotic-resistant Acinetobacter baumannii.
- ceftazidime refers to (6R,7R)-7-[[(2Z)-2-(2-Aminothiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-8-oxo-3-[(1-pyridinio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, or its hydrates, solvates, polymorphs and/or pharmaceutical salts thereof.
- Examples include ceftazidime pentahydrate, ceftazidime sodium, etc.
- the amount described in the present invention is calculated based on (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-8-oxo-3-[(1-pyridiniolmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate.
- sulbactam refers to (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide, or its hydrates, solvates, polymorphs and/or pharmaceutical salts thereof. Examples include sulbactam sodium, etc.
- the amount described in the present invention is calculated based on (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide.
- composition of sulbactam and ceftazidime may contain pharmaceutically applicable excipients according to the dosage form.
- CLSI refers to the Clinical & Laboratory Standards Institute.
- CLSI-M100 is Performance Standards for Antimicrobial Susceptibility Tests.
- CLSI-M02 is Performance Standards for Antimicrobial Disk Susceptibility Tests.
- CLSI-M07 is Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically.
- CLSI also regularly revises the documents published. A person skilled in the art would be aware that the latest CLSI documents have the greatest reference value.
- MIC i.e. the minimal inhibitory concentration
- the bacteria are cultured at 37° C. for 24 h.
- resistant in the expression “resistant Acinetobacter baumannii ” means that according to the CLSI method (disk method or dilution method), Acinetobacter baumannii is tested with a drug, and the result is interpreted as resistance according to the CLSI-M100 standard.
- Sulbactam and ceftazidime were taken and prepared into compositions of different ratios.
- the method was fixing the amount of sulbactam and gradually reducing the amount of ceftazidime to obtain compositions of sulbactam and ceftazidime at weight ratios of 1:1, 1:0.9, 1:0.8, 1:0.6, 1:0.4, 1:0.2 and 1:0.1, respectively.
- a sulbactam-only preparation was additionally used as a control.
- the cumulative microbial inhibition rate was used to evaluate the microbial inhibition effects of the drugs, respectively.
- the cumulative microbial inhibition rate was defined as the microbial inhibition rate of a drug at a certain concentration plus all the microbial inhibition rates below that concentration.
- the microbial inhibition rate of a drug at a certain concentration (the number of strains whose growth was inhibited at that drug concentration ⁇ the total number of strains) ⁇ 100%. The lower the drug concentration and the higher the cumulative microbial inhibition rate, the better the microbial inhibition effects.
- compositions of sulbactam and low-proportion ceftazidime showed better effects against carbapenem-resistant Acinetobacter baumannii .
- concentration-cumulative microbial inhibition rate curves of the compositions of sulbactam and low-proportion ceftazidime shifted significantly to the left, indicating that the microbial inhibition effects were significantly enhanced.
- the compositions in the ratio range of 1:(0.8-0.2) showed superior effects.
- the results showed that the low-proportion ceftazidime unexpectedly and significantly enhanced the antimicrobial effects of sulbactam against carbapenem-resistant Acinetobacter baumannii.
- Drugs The four compositions of sulbactam and ceftazidime prepared at ratios of 1:1, 1:0.8, 1:0.4 and 1:0.2 in Example 1 were taken.
- Samples were respectively taken at the time points of 0, 2 h, 4 h, 6 h, 8 h, 12 h and 24 h, diluted by 10 times, and then inoculated on agar plates.
- the agar plates were placed in an incubator at 37° C. and cultured for 24 hours, followed by bacterial counting, and the data of the five strains were averaged and then analyzed as one datum.
- the difference of the bacterial counts log 10 CFU per ml between before and after administration indicated the strength of microbicidal activity.
- ⁇ log 10 CFU/ml was defined as the bacterial log 10 CFU/ml after administration minus the bacterial log 10 CFU/ml before administration. At the same sampling time, the smaller the ⁇ log 10 CFU/ml, the better the microbicidal effect.
- Tables 2-5 listed the differences of the bacterial counts of CR-Ab between before and after the composition with each ratio was added. Taking the sampling time as the abscissa and the difference of the bacterial counts between before and after administration, ⁇ log 10 CFU/ml, as the ordinate, time-microbicidal curves were plotted, as shown in FIG. 2 (A was 1:1 sulbactam and ceftazidime, B was 1:0.8 sulbactam and ceftazidime, C was 1:0.4 sulbactam and ceftazidime, and D was 1:0.2 sulbactam and ceftazidime).
- Drugs The compositions of sulbactam and ceftazidime at ratios of 1:1, 1:0.9, 1:0.8, 1:0.6, 1:0.4, 1:0.2 and 1:0.1, as used in Example 1, were prepared into drug solutions with water for injection; commercially available meropenem was prepared into drug solutions with water for injection; and commercially available meropenem plus sulbactam was prepared into 1:1 drug solutions of meropenem and sulbactam with water for injection.
- CR-Ab strains were used and cultured into a bacterial suspension with a concentration of 10 8 CFU/mL.
- mice Male C57BL/6 mice were randomly divided into a normal control group, a model control group, a meropenem group, a 1:1 meropenem and sulbactam group, a 1:1 sulbactam and ceftazidime group, a 1:0.9 sulbactam and ceftazidime group, a 1:0.8 sulbactam and ceftazidime group, a 1:0.6 sulbactam and ceftazidime group, a 1:0.4 sulbactam and ceftazidime group, a 1:0.2 sulbactam and ceftazidime group and a 1:0.1 sulbactam and ceftazidime group. Each group was divided into two subgroups, low-dose and high-dose, and each subgroup was assigned 15 animals.
- mice in each group were intraperitoneally injected with 50 mg/kg of cyclophosphamide, and further intraperitoneally injected with 50 mg/kg of cyclophosphamide after 3 days. Then, 1 day later, except the normal control group, the mice in each group were respectively injected with 80 ⁇ L of the bacterial suspension through the airway, and the mice in the normal control group were injected with the same amount of normal saline.
- mice in each group except the normal control group and the model control group, were respectively intraperitoneally injected with a low dose (10 mg/kg) and a high dose (30 mg/kg) of the drug for each group, and the mice in the normal control group and the model control group were injected with the same amount of normal saline.
- the administration frequency was once a day. After 7 days, the number of surviving mice was counted.
- mice listed the main results of the test. Cyclophosphamide is an immunosuppressant, the injection of which led to that the immunity of mice was reduced and the mice were more susceptible to CR-Ab infection.
- the mice in each group showed obvious shortness of breath, decreased activity, and slow response during the test period. Almost all mice in the model control group died after 7 days. Autopsy of the dead mice revealed severe inflammatory changes in the lungs, including typical pneumonia pathological changes such as bronchial wall thickening, bronchiectasis, monocyte exudation, and severe pulmonary interstitial congestion, indicating that the modeling was successful.
- compositions of sulbactam and low-proportion ceftazidime (1:(0.2-0.8)) could better protect infected mice, the effect of which was significantly better than that of the 1:1 composition of sulbactam and ceftazidime, and even superior to that of the composition of carbapenem and sulbactam.
- sulbactam could inhibit 0-lactamases to overcome bacterial resistance, and on the other hand, it could also exert the antibacterial effect by binding to penicillin-binding proteins (PBPs) of Acinetobacter baumannii .
- PBPs penicillin-binding proteins
- This dual effect had certain advantages.
- the effect of using sulbactam alone was not good.
- Carbapenem antibiotic-resistant Acinetobacter baumannii (CR-Ab) was generally highly resistant to ceftazidime, and the use of ceftazidime alone also made little sense.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application of a sulbactam and ceftazidime composition in the preparation of a drug for treating a carbapenem-resistant antibiotic Acinetobacter baumannii infection, characterized in the following: by mass, the amount of ceftazidime used in the sulbactam and ceftazidime composition comprising 10% to 90% of the amount of sulbactam used.
Description
The present application is a national phase entry under 35 USC § 371 of International Application PCT/CN2020/076032, filed on Feb. 20, 2020, which claims the benefit of and priority to Chinese Patent Application No. 2019101625544, filed on Mar. 5, 2019, the entire disclosures of which are incorporated herein by reference.
The present invention relates to the field of medicine, and in particular to a method and a composition for treating diseases caused by Acinetobacter baumannii infections, especially by carbapenem antibiotic-resistant Acinetobacter baumannii infections.
Acinetobacter baumannii is a non-fermenting Gram-negative bacterium and is an important pathogen. It is widely recognized that Acinetobacter baumannii is an important cause of serious infections. Clinically, serious infections in systems such as respiratory, blood, abdominal cavity, central nervous system, urinary and skin soft tissues are closely related to Acinetobacter baumannii.
Xiangxin L I et al. (Chinese Journal of Antibiotics, 2007, 32(12): 762-764) retrospectively investigated the clinical distribution of clinically isolated Acinetobacter baumannii from January 2002 to December 2006, and found that among 865 strains of Acinetobacter baumannii isolated within the 5 years, 75.7% were mainly derived from respiratory tract specimens. Chengdong S U N et al. (Chinese Critical Care Medicine, 2013, 25(6): 369-372) collected various microbial test specimens from inpatients in Beijing Jishuitan Hospital from January 2009 to December 2012 and isolated totally 307 strains of pandrug-resistant Acinetobacter baumannii in 4 years, which were originated mainly from respiratory tract secretions (69.4%) and secondly from wound surface secretions (14.7%), wherein the detection rates in the intensive care unit (ICU, 26.4%), respiratory department (26.1%), and geriatric department (23.1%) were the highest. Yili L I U et al. (International Journal of Laboratory Medicine, 2015(13): 1899-1901) carried out retrospective statistical analysis on the specimen source, ward distribution and drug-resistance evolution of 1678 strains of Acinetobacter baumannii isolated in Pudong Hospital Affiliated to Fudan University from January 2010 to October 2014, and the results showed that the clinically isolated Acinetobacter baumannii was mainly originated from respiratory tract specimens (79.1%), and the ward distribution was mainly in the intensive care unit (21.1%), neurosurgery department (17.7%) and cardiology department (17.6%).
A variety of antimicrobial drugs have varying degrees of antimicrobial activities against Acinetobacter baumannii, and each has its own advantages and disadvantages. Examples include antibiotics of cephalosporins, quinolones, sulbactam and sulbactam-containing compound preparations, carbapenems, colistins, glycylcyclines, and aminoglycoside, etc. Among them, colistins have the best antimicrobial effect against Acinetobacter baumannii; however, the tolerance is relatively poor. The hepatic and renal toxicity of glycylcyclines, aminoglycosides etc. is relatively high. Quinolones have a disabling risk. High adverse reactions often limit the clinical application of drugs. Cephalosporins have a relatively good safety. For example, the third-generation cephalosporin, ceftazidime has a relatively good antimicrobial effect on Gram-negative bacteria, especially possessing the best effect against Pseudomonas aeruginosa; however, its antimicrobial effect on Acinetobacter baumannii is moderate. Sulbactam also has a relatively good safety; however, sulbactam has always been used as a β-lactamase inhibitor in combination with other β-lactam antibiotics to improve the antimicrobial activity of the antibiotics, and representative sulbactam-containing compound preparations include ampicillin/sulbactam, cefoperazone/sulbactam etc.; furthermore, sulbactam itself has only a moderate degree of activity against Acinetobacter baumannii. Carbapenem antibiotics, such as imipenem, meropenem, panipenem, biapenem and doripenem, are very stable against β-lactamases and have strong antimicrobial effects, among which imipenem and meropenem are representatives; however, they are not as safe as cephalosporins and are strictly controlled in clinical use.
In recent years, the resistance of Acinetobacter baumannii to antimicrobial drugs has become increasingly serious.
For example, Xiangxin L I et al. as mentioned above found that the resistance of Acinetobacter baumannii clinically isolated from January 2002 to December 2006 to commonly used antimicrobial drugs increased year by year; Chengdong S U N et al. as mentioned above found that the resistance rate of Acinetobacter baumannii clinically isolated from the inpatients in Beijing Jishuitan Hospital from January 2009 to December 2012 to cefotaxime, piperacillin, meropenem, imipenem, ciprofloxacin, tetracycline etc. could be up to 100%; and Yili L I U et al. as mentioned above found that the 1678 strains of Acinetobacter baumannii isolated in Pudong Hospital affiliated to Fudan University from January 2010 to October 2014 were highly resistant to the first-generation and second-generation cephalosporins, cephamycins, ampicillin and nitrofurantoin, with the resistance rate reaching 90% or higher. The resistance rate to carbapenem antimicrobials, aztreonam, cefoperazone/sulbactam, and ampicillin/sulbactam also showed a significantly increasing trend. China Antimicrobial Surveillance Network (http://www.sific.com.cn/InsidePage/1000/67/7970.html) found in 2017 that clinically isolated Acinetobacter baumannii had a resistance rate of up to 72% to ceftazidime, up to 62.1% to ampicillin/sulbactam, up to 66.7% to imipenem, up to 69.3% to meropenem, and up to 43.5% to cefoperazone/sulbactam. According to the ranking of top 12 drug-resistant bacteria published by the World Health Organization in 2017, Acinetobacter baumannii was ranked No. 1 in the term of severe drug resistance level.
Sulbactam-related preparations have attracted attention in the treatment of drug-resistant Acinetobacter baumannii infections due to the better safety. Sulbactam itself has a relatively high MIC value for Acinetobacter baumannii and a limited antimicrobial effect. The synergistic effect of sulbactam-containing compound preparations on drug-resistant Acinetobacter baumannii has been studied.
Hua T A N et al. (Chinese Journal of Antibiotics, 2006, 31(8): 488-491) studied the effect of sulbactam combinations on cephalosporin-resistant Acinetobacter baumannii, wherein clinically isolated 56 strains of Acinetobacter baumannii resistant or intermediate to cefoperazone (CPZ), ceftazidime (CAZ) or cefotaxime (CTX) were divided into three groups: Group A was resistant to two or more of the above-mentioned drugs, Group B was resistant to CPZ only, and Group C was intermediate to CPZ or CTX. The minimal inhibitory concentrations (MICs) of single sulbactam and sulbactam combined with the above-mentioned three third-generation cephalosporins, were detected respectively by broth microdilution method. It was found that none of the combinations of sulbactam and any drug of CPZ, CAZ or CTX at the concentration of susceptibility and resistance breakpoint could cause the MICs of the sulbactam combination to be lower than that of single sulbactam. It was concluded that the single sulbactam had antimicrobial activity against multi-drug resistant Acinetobacter baumannii; however, the susceptibility of these strains to the combination preparations may be mainly due to the microbicidal effect of sulbactam.
Yishan HUANG et al. (China Practical Medicine, 2009, 4(31): 34-35) found that the application of sulbactam combined with third-generation cephalosporins could effectively reduce the MIC value of the third-generation cephalosporins against multi-drug resistant Acinetobacter baumannii, and for strains resistant to third-generation cephalosporins, the combination preparation could reduce the MIC to a susceptible range in case of a certain drug concentration being reached. However, from the data in the article, it can be seen that for imipenem-resistant Acinetobacter baumannii in Group C, although the use of sulbactam combined with ceftazidime reduced the MIC value of ceftazidime, without reducing the value to a susceptible range (according to CLSI standards, the MIC value of ceftazidime susceptible to Acinetobacter baumannii is ≤8 μg/ml), indicating that the clinical effect of the combined use of the two substances is not good.
Menglan ZHOU et al. (Chinese Journal of Clinical Laboratory Science, 2018, 36(1): 22-24) selected 23 strains of clinically meropenem-resistant Acinetobacter baumannii and 21 strains of meropenem-susceptible Acinetobacter baumannii, carried out a combined drug susceptibility test by the checkerboard dilution method, and calculated the fractional inhibitory concentration index (FIC) to determine the effect of combinations (synergy, partial synergy, irrelevance or antagonism). The results showed that the antimicrobial effect of the combined application of cefoperazone, tigecycline and sulbactam on Acinetobacter baumannii was mainly synergistic; the antimicrobial effect of the combined application of imipenem, colistin and sulbactam on Acinetobacter baumannii was mainly manifested as synergy and partial synergy; and the combined application of ceftazidime and sulbactam was mainly manifested as an irrelevant effect. From the data in the article, it can be seen that for meropenem-resistant Acinetobacter baumannii MRAB, cephalosporins combined with sulbactam did not show a synergistic effect, while cefoperazone combined with sulbactam mainly showed an additive effect (43.5%), and ceftazidime combined with sulbactam mainly showed an irrelevant effect (52.2%).
The resistance mechanisms of bacteria are quite complicated, and there are differences among different bacteria. The resistance mechanisms of Acinetobacter baumannii mainly include: (1) production of enzymes which inactivate antimicrobial drugs, including: 1) (3-lactamases: TEM-type and SHY-type enzymes of class A, metallo-β-lactamases of class B, AmpC-type enzymes of class C, OXA-type enzymes of class D, etc.; and 2) aminoglycoside modifying enzymes; (2) changes in target sites of drug action: topoisomerases, 16S rRNA methylase gene mutations, etc.; and (3) decrease in the amount of drugs reaching the target sites of action, including a decrease in the permeability of outer membrane porin and the overexpression of efflux pumps. The genome of Acinetobacter baumannii has shown that it is rich in efflux pump genes, and the high expression of efflux pumps plays an important role in the multi-drug resistance of Acinetobacter baumannii. (Qiuping L I U et al., Chinese Journal of Antibiotics, 2018, 43(10): 1179-1187)
The resistance of Acinetobacter baumannii to cephalosporins is mainly due to the production of large amounts of AmpC cephalosporinases. Since carbapenem antibiotics are highly stable against AmpC-type enzymes, clinically, carbapenem antibiotics are generally used for the treatment of cephalosporin-resistant Acinetobacter baumannii infection. However, for carbapenem-resistant Acinetobacter baumannii, the resistance mechanism is different, which is mainly attributed to production of OXA-type carbapenemases, in addition, down-regulation of membrane channel protein expression, over-expression of drug efflux pump, etc. also play important roles. Therefore, for Acinetobacter baumannii infections with different drug resistances, targeted treatment is required. However, for carbapenem antibiotic-resistant Acinetobacter baumannii infections, effective antibiotic compositions are lacking currently.
An object of the present invention is to provide the use of a composition of sulbactam and ceftazidime in the preparation of a medicament for treating the infection with carbapenem antibiotic-resistant Acinetobacter baumannii.
Another object of the present invention is to provide a method for treating the infection with carbapenem antibiotic-resistant Acinetobacter baumannii.
A further object of the present invention is to provide a composition of sulbactam and ceftazidime for treating the infection with carbapenem antibiotic-resistant Acinetobacter baumannii.
The technical solutions used by the present invention are as follows:
Use of a composition of sulbactam and ceftazidime in the preparation of a medicament for treating the infection with carbapenem antibiotic-resistant Acinetobacter baumannii, wherein the amount of ceftazidime in the sulbactam and ceftazidime composition is 10%-90% by mass of the amount of sulbactam.
In some embodiments, the amount of ceftazidime in the sulbactam and ceftazidime composition is 20%-80% of the amount of sulbactam.
In some embodiments, the amount of ceftazidime in the sulbactam and ceftazidime composition is 20%-40% of the amount of sulbactam.
In some embodiments, the amount of ceftazidime in the sulbactam and ceftazidime composition is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the amount of sulbactam.
In some embodiments, the carbapenem antibiotic is at least one of meropenem, imipenem, panipenem, biapenem or doripenem.
In some embodiments, the carbapenem antibiotic-resistant Acinetobacter baumannii is also resistant to ceftazidime.
In some embodiments, the sulbactam and ceftazidime composition is a non-oral preparation.
In some embodiments, the sulbactam and ceftazidime composition is an injection or an inhalant.
In some embodiments, sulbactam and ceftazidime in the sulbactam and ceftazidime composition may be individually packaged (that is, the two are packaged separately and then combined), or may also be mixed packaged (that is, the two are mixed and then packaged). The two may be used in the form of a compound preparation after being mixed, or may also be used in combination in the form of single preparations.
In some embodiments, the daily dose of sulbactam in the sulbactam and ceftazidime composition is 2 g-20 g. It can be administered 2 to 4 times a day in divided doses.
In some embodiments, the daily dose of ceftazidime in the sulbactam and ceftazidime composition is 0.2 g-18 g. It can be administered 2 to 4 times a day in divided doses.
A method for treating the infection with carbapenem antibiotic-resistant Acinetobacter baumannii is provided, comprising administering to a patient therapeutically effective amounts of sulbactam and ceftazidime, wherein the amount of ceftazidime is 10%-90%, 20%-80% or 20%-40% by mass of the amount of sulbactam.
In some embodiments, the amount of ceftazidime is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the amount of sulbactam.
In some embodiments, the carbapenem antibiotic-resistant Acinetobacter baumannii is resistant to at least one carbapenem antibiotic of meropenem, imipenem, panipenem, biapenem or doripenem.
In some embodiments, Acinetobacter baumannii is also resistant to ceftazidime.
In some embodiments, sulbactam and ceftazidime are used in the form of a compound preparation.
In some embodiments, sulbactam and ceftazidime are used in combination in the form of single preparations.
In some embodiments, the administration route is non-oral administration, preferably injection administration or inhalation administration.
The dose of administration may be adjusted according to the clinical severity of the disease. In some embodiments, the daily dose of sulbactam may be 2 g-20 g, and the daily dose of ceftazidime may be 0.2 g-18 g. It can be administered 2 to 4 times a day in divided doses.
A composition of sulbactam and ceftazidime for treating the carbapenem antibiotic-resistant Acinetobacter baumannii infection is provided, wherein the amount of ceftazidime in the sulbactam and ceftazidime composition is 10%-90%, 20%-80% or 20%-40% by mass of the amount of sulbactam.
In some embodiments, the carbapenem antibiotic-resistant Acinetobacter baumannii is resistant to at least one carbapenem antibiotic of meropenem, imipenem, panipenem, biapenem or doripenem.
In some embodiments, Acinetobacter baumannii is also resistant to ceftazidime.
In some embodiments, sulbactam and ceftazidime are packaged individually or in a mixed manner.
In some embodiments, the sulbactam and ceftazidime composition is a non-oral preparation. Furthermore, it is an injection or an inhalant.
In some embodiments, the sulbactam and ceftazidime composition can unexpectedly effectively treat the infections with carbapenem antibiotic-resistant Acinetobacter baumannii, and the therapeutic effect is even superior than that of a composition of carbapenem antibiotics and sulbactam.
The present invention will be described in detail below with specific embodiments. It should be understood that the content of the DETAILED DESCRIPTION section is illustrative rather than restrictive, that is, it does not impose any restriction on the content of the present invention.
The term “ceftazidime” refers to (6R,7R)-7-[[(2Z)-2-(2-Aminothiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-8-oxo-3-[(1-pyridinio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, or its hydrates, solvates, polymorphs and/or pharmaceutical salts thereof. Examples include ceftazidime pentahydrate, ceftazidime sodium, etc. The amount described in the present invention is calculated based on (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-8-oxo-3-[(1-pyridiniolmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate.
The term “sulbactam” refers to (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide, or its hydrates, solvates, polymorphs and/or pharmaceutical salts thereof. Examples include sulbactam sodium, etc. The amount described in the present invention is calculated based on (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide.
The “composition of sulbactam and ceftazidime” of the present invention may contain pharmaceutically applicable excipients according to the dosage form.
The term “CLSI” refers to the Clinical & Laboratory Standards Institute. Various publications published by CLSI are well known in the art. For example, CLSI-M100 is Performance Standards for Antimicrobial Susceptibility Tests. CLSI-M02 is Performance Standards for Antimicrobial Disk Susceptibility Tests. CLSI-M07 is Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. CLSI also regularly revises the documents published. A person skilled in the art would be aware that the latest CLSI documents have the greatest reference value.
The term “MIC”, i.e. the minimal inhibitory concentration, refers to the lowest concentration at which a drug can prevents the visible growth of bacteria (the bacteria are cultured at 37° C. for 24 h).
The term “resistant” in the expression “resistant Acinetobacter baumannii” means that according to the CLSI method (disk method or dilution method), Acinetobacter baumannii is tested with a drug, and the result is interpreted as resistance according to the CLSI-M100 standard.
Strains: 157 clinically isolated strains of carbapenem antibiotic-resistant Acinetobacter baumannii were selected and named as CR-Ab. Selection criteria: The clinically isolated Acinetobacter baumannii was subjected to susceptibility testing using imipenem and meropenem (the commonly used representatives of carbapenems) according to the CLSI disk method, and the inclusion criteria was that the result of the susceptibility test showed resistance to one or both of meropenem or imipenem. Resistance refers to the MIC of imipenem and/or meropenem ≥8 μg/ml according to the criteria of Table 2B-2 of CLSI-M100 27th edition.
Drugs: Sulbactam and ceftazidime were taken and prepared into compositions of different ratios. The method was fixing the amount of sulbactam and gradually reducing the amount of ceftazidime to obtain compositions of sulbactam and ceftazidime at weight ratios of 1:1, 1:0.9, 1:0.8, 1:0.6, 1:0.4, 1:0.2 and 1:0.1, respectively. A sulbactam-only preparation was additionally used as a control.
Method: According to the CLSI broth microdilution method (the drug dilution concentration was 0.125-512 μg/ml), 157 strains of CR-Ab were subjected to susceptibility testing, and the MIC value of each composition was determined (the MIC value of sulbactam in the composition as the representative). The cumulative microbial inhibition rate was used to evaluate the microbial inhibition effects of the drugs, respectively. The cumulative microbial inhibition rate was defined as the microbial inhibition rate of a drug at a certain concentration plus all the microbial inhibition rates below that concentration. The microbial inhibition rate of a drug at a certain concentration=(the number of strains whose growth was inhibited at that drug concentration÷the total number of strains)×100%. The lower the drug concentration and the higher the cumulative microbial inhibition rate, the better the microbial inhibition effects.
Results: The cumulative microbial inhibition rate of each composition against carbapenem-resistant Acinetobacter baumannii CR-Ab was shown in Table 1, and taking the drug concentration as the abscissa and the cumulative microbial inhibition rate as the ordinate, concentration-cumulative microbial inhibition rate curves were plotted, as shown in FIG. 1 .
| TABLE 1 |
| Cumulative microbial inhibition rates (%) of sulbactam:ceftazidime |
| at different ratios against CR-Ab |
| Drug concentration | Compositions with different ratios (sulbactam:ceftazidime) | Single |
| (sulbactam, μg/ml) | 1:1 | 1:0.9 | 1:0.8 | 1:0.6 | 1:0.4 | 1:0.2 | 1:0.1 | sulbactam |
| 0.125 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| 0.25 | 0 | 0 | 5 | 8 | 11 | 15 | 0 | 0 |
| 0.5 | 0 | 6 | 16 | 22 | 29 | 33 | 4 | 0 |
| 1 | 5 | 16 | 32 | 36 | 49 | 51 | 13 | 7 |
| 2 | 13 | 29 | 48 | 54 | 66 | 73 | 29 | 17 |
| 4 | 22 | 42 | 68 | 76 | 82 | 87 | 46 | 32 |
| 8 | 34 | 59 | 84 | 90 | 95 | 100 | 67 | 48 |
| 16 | 49 | 75 | 94 | 98 | 100 | 100 | 83 | 64 |
| 32 | 73 | 97 | 100 | 100 | 100 | 100 | 95 | 84 |
| 64 | 91 | 100 | 100 | 100 | 100 | 100 | 100 | 94 |
| 128 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| 256 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| 512 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
It could be seen from Table 1 and FIG. 1 that compositions of sulbactam and low-proportion ceftazidime showed better effects against carbapenem-resistant Acinetobacter baumannii. Compared with the 1:1 composition of sulbactam and ceftazidime or the sulbactam-only preparation, the concentration-cumulative microbial inhibition rate curves of the compositions of sulbactam and low-proportion ceftazidime shifted significantly to the left, indicating that the microbial inhibition effects were significantly enhanced. In particular, the compositions in the ratio range of 1:(0.8-0.2) showed superior effects. The results showed that the low-proportion ceftazidime unexpectedly and significantly enhanced the antimicrobial effects of sulbactam against carbapenem-resistant Acinetobacter baumannii.
Strains: The carbapenem antibiotic-resistant Acinetobacter baumannii CR-Ab in Example 1 was taken.
Drugs: The four compositions of sulbactam and ceftazidime prepared at ratios of 1:1, 1:0.8, 1:0.4 and 1:0.2 in Example 1 were taken.
Method: Five CR-Ab strains were selected and subjected to susceptibility testing using each of these compositions to obtain the respective MIC value thereof. Subsequently, bacterial suspension with a concentration of 106 CFU/mL obtained after culturing the strain with an MH broth (Mueller-Hinton broth) was used as an inoculum. The inoculum was taken separately, each drug composition was added such that the final concentrations of the drug (based on the sulbactam concentration) were respectively 0 (negative control), 0.25 MIC, 1 MIC, 2 MIC, 4 MIC, 8 MIC and 16 MIC. Samples were respectively taken at the time points of 0, 2 h, 4 h, 6 h, 8 h, 12 h and 24 h, diluted by 10 times, and then inoculated on agar plates. The agar plates were placed in an incubator at 37° C. and cultured for 24 hours, followed by bacterial counting, and the data of the five strains were averaged and then analyzed as one datum. The difference of the bacterial counts log 10 CFU per ml between before and after administration (Δ log 10 CFU/ml) indicated the strength of microbicidal activity. Δ log 10 CFU/ml was defined as the bacterial log 10 CFU/ml after administration minus the bacterial log 10 CFU/ml before administration. At the same sampling time, the smaller the Δ log 10 CFU/ml, the better the microbicidal effect.
Results: Tables 2-5 listed the differences of the bacterial counts of CR-Ab between before and after the composition with each ratio was added. Taking the sampling time as the abscissa and the difference of the bacterial counts between before and after administration, Δ log 10 CFU/ml, as the ordinate, time-microbicidal curves were plotted, as shown in FIG. 2 (A was 1:1 sulbactam and ceftazidime, B was 1:0.8 sulbactam and ceftazidime, C was 1:0.4 sulbactam and ceftazidime, and D was 1:0.2 sulbactam and ceftazidime). It could be seen from the results that compared with the 1:1 composition of sulbactam and ceftazidime, the long-term microbicidal effects of sulbactam and low-proportion ceftazidime (1:(0.8-0.2)) were significantly stronger, indicating there were unexpected effects.
| TABLE 2 |
| Difference of the bacterial counts of CR-Ab between before and |
| after 1:1 sulbactam and ceftazidime was added (Δlog10 CFU/ml) |
| Drug concentration (sulbactam) |
| Sampling | Negative | |||||||
| time (h) | control | 0.25MIC | 1MIC | 2MIC | | 8MIC | 16MIC | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 0.82 | 0.62 | −0.11 | −0.13 | −0.42 | −0.65 | −0.84 |
| 4 | 2.21 | 1.64 | −0.23 | −0.32 | −0.78 | −0.93 | −1.04 |
| 6 | 3.11 | 2.42 | −0.24 | −0.43 | −0.85 | −1.04 | −1.12 |
| 8 | 3.35 | 2.65 | −0.21 | −0.44 | −0.88 | −1.22 | −1.24 |
| 12 | 3.52 | 2.96 | −0.2 | −0.46 | −0.88 | −1.25 | −1.31 |
| 24 | 3.63 | 3.04 | −0.23 | −0.47 | −0.92 | −1.25 | −1.32 |
| TABLE 3 |
| Difference of the bacterial counts of CR-Ab between before and |
| after 1:0.8 sulbactam and ceftazidime was added (Δlog10 CFU/ml) |
| Drug concentration (sulbactam) |
| Sampling | Negative | |||||||
| time (h) | control | 0.25MIC | 1MIC | 2MIC | | 8MIC | 16MIC | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 1.43 | 0.82 | −0.07 | −0.77 | −1.56 | −2.27 | −2.55 |
| 4 | 2.91 | 2.13 | −0.11 | −1.35 | −2.13 | −2.86 | −3.16 |
| 6 | 3.72 | 2.64 | −0.21 | −1.74 | −2.55 | −3.25 | −3.57 |
| 8 | 4.12 | 3.01 | −0.33 | −1.86 | −2.67 | −3.38 | −3.66 |
| 12 | 4.35 | 3.33 | −0.42 | −1.98 | −2.77 | −3.46 | −3.83 |
| 24 | 4.41 | 3.44 | −0.44 | −1.97 | −2.91 | −3.57 | −3.96 |
| TABLE 4 |
| Difference of the bacterial counts of CR-Ab between before and |
| after 1:0.4 sulbactam and ceftazidime was added (Δlog10 CFU/ml) |
| Drug concentration (sulbactam) |
| Sampling | Negative | |||||||
| time (h) | control | 0.25MIC | 1MIC | 2MIC | | 8MIC | 16MIC | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 1.03 | 0.55 | −0.24 | −1.23 | −2.05 | −2.71 | −3.03 |
| 4 | 2.52 | 1.63 | −0.56 | −1.84 | −2.63 | −3.34 | −3.61 |
| 6 | 3.33 | 2.25 | −0.77 | −2.25 | −3.02 | −3.73 | −4.01 |
| 8 | 3.76 | 2.66 | −0.95 | −2.33 | −3.15 | −3.85 | −4.14 |
| 12 | 3.91 | 2.93 | −1.03 | −2.46 | −3.22 | −3.94 | −4.33 |
| 24 | 4.06 | 3.03 | −1.12 | −2.48 | −3.35 | −4.03 | −4.42 |
| TABLE 5 |
| Difference of the bacterial counts of CR-Ab between before and |
| after 1:0.2 sulbactam and ceftazidime was added (Δlog10 CFU/ml) |
| Drug concentration (sulbactam) |
| Sampling | Negative | |||||||
| time (h) | control | 0.25MIC | 1MIC | 2MIC | | 8MIC | 16MIC | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 0.91 | 0.43 | −0.34 | −1.32 | −2.21 | −3.03 | −3.33 |
| 4 | 2.42 | 1.84 | −0.52 | −1.73 | −2.63 | −3.54 | −3.82 |
| 6 | 3.22 | 2.34 | −0.74 | −2.12 | −3.03 | −3.83 | −4.25 |
| 8 | 3.64 | 2.76 | −1.05 | −2.44 | −3.32 | −4.06 | −4.36 |
| 12 | 3.82 | 3.05 | −1.24 | −2.51 | −3.43 | −4.34 | −4.57 |
| 24 | 3.93 | 3.14 | −1.36 | −2.64 | −3.57 | −4.52 | −4.74 |
It could be seen from the results that compared with the 1:1 composition of sulbactam and ceftazidime, the long-term microbicidal effects of sulbactam and low-proportion ceftazidime (1:(0.2-0.8)) were significantly superior, indicating there were unexpected effects.
Drugs: The compositions of sulbactam and ceftazidime at ratios of 1:1, 1:0.9, 1:0.8, 1:0.6, 1:0.4, 1:0.2 and 1:0.1, as used in Example 1, were prepared into drug solutions with water for injection; commercially available meropenem was prepared into drug solutions with water for injection; and commercially available meropenem plus sulbactam was prepared into 1:1 drug solutions of meropenem and sulbactam with water for injection.
Strains: CR-Ab strains were used and cultured into a bacterial suspension with a concentration of 108 CFU/mL.
Animals: Male C57BL/6 mice were randomly divided into a normal control group, a model control group, a meropenem group, a 1:1 meropenem and sulbactam group, a 1:1 sulbactam and ceftazidime group, a 1:0.9 sulbactam and ceftazidime group, a 1:0.8 sulbactam and ceftazidime group, a 1:0.6 sulbactam and ceftazidime group, a 1:0.4 sulbactam and ceftazidime group, a 1:0.2 sulbactam and ceftazidime group and a 1:0.1 sulbactam and ceftazidime group. Each group was divided into two subgroups, low-dose and high-dose, and each subgroup was assigned 15 animals.
Test method: Except the normal control group, the mice in each group were intraperitoneally injected with 50 mg/kg of cyclophosphamide, and further intraperitoneally injected with 50 mg/kg of cyclophosphamide after 3 days. Then, 1 day later, except the normal control group, the mice in each group were respectively injected with 80 μL of the bacterial suspension through the airway, and the mice in the normal control group were injected with the same amount of normal saline. Starting from 1 day before the injection of the bacterial suspension, the mice in each group, except the normal control group and the model control group, were respectively intraperitoneally injected with a low dose (10 mg/kg) and a high dose (30 mg/kg) of the drug for each group, and the mice in the normal control group and the model control group were injected with the same amount of normal saline. The administration frequency was once a day. After 7 days, the number of surviving mice was counted.
Results: Table 6 listed the main results of the test. Cyclophosphamide is an immunosuppressant, the injection of which led to that the immunity of mice was reduced and the mice were more susceptible to CR-Ab infection. The mice in each group showed obvious shortness of breath, decreased activity, and slow response during the test period. Almost all mice in the model control group died after 7 days. Autopsy of the dead mice revealed severe inflammatory changes in the lungs, including typical pneumonia pathological changes such as bronchial wall thickening, bronchiectasis, monocyte exudation, and severe pulmonary interstitial congestion, indicating that the modeling was successful. From the survival of the mice in each group after 7 days, it could be seen that the compositions of sulbactam and low-proportion ceftazidime (1:(0.2-0.8)) could better protect infected mice, the effect of which was significantly better than that of the 1:1 composition of sulbactam and ceftazidime, and even superior to that of the composition of carbapenem and sulbactam.
| TABLE 6 |
| Survival of CR-Ab pneumonia model |
| mice (survival number/total number) |
| Group | Low dose | High dose |
| Normal control group | 15/15 | 14/15 |
| | 1/15 | 0/15 |
| Meropenem group | 2/15 | 3/15 |
| 1:1 meropenem and | 8/15 | 9/15 |
| 1:1 sulbactam and ceftazidime group | 4/15 | 5/15 |
| 1:0.9 sulbactam and ceftazidime group | 9/15 | 9/15 |
| 1:0.8 sulbactam and ceftazidime group | 12/15 | 14/15 |
| 1:0.6 sulbactam and ceftazidime group | 12/15 | 15/15 |
| 1:0.4 sulbactam and ceftazidime group | 13/15 | 15/15 |
| 1:0.2 sulbactam and ceftazidime group | 14/15 | 15/15 |
| 1:0.1 sulbactam and | 10/15 | 10/15 |
Possible Mechanisms of Action
On the one hand, sulbactam could inhibit 0-lactamases to overcome bacterial resistance, and on the other hand, it could also exert the antibacterial effect by binding to penicillin-binding proteins (PBPs) of Acinetobacter baumannii. This dual effect had certain advantages. However, the effect of using sulbactam alone was not good. Carbapenem antibiotic-resistant Acinetobacter baumannii (CR-Ab) was generally highly resistant to ceftazidime, and the use of ceftazidime alone also made little sense.
The above-mentioned experimental data indicated that the use of sulbactam and ceftazidime in combination at a specific ratio had an excellent therapeutic effect on CR-Ab infection, and the therapeutic effect thereof was even stronger than that of the composition of carbapenem and sulbactam. The possible reasons were as follows: on the one hand, since CR-Ab was highly resistant to ceftazidime, and the 0-lactamases produced by CR-Ab had a strong affinity for ceftazidime, so the addition of ceftazidime could protect sulbactam from being hydrolyzed by the 0-lactamases to some extent; furthermore, ceftazidime could also reduce the chance of sulbactam being effluxed by occupying drug efflux pumps. On the other hand, since sulbactam needed to bind to the PBPs of Acinetobacter baumannii to exert the antimicrobial effect, and the affinity of ceftazidime to the PBPs was greater than that of sulbactam, thus the occupation of the PBP targets by too much ceftazidime was not conducive to the antimicrobial effect of sulbactam. Therefore, the amount of ceftazidime needed to be controlled within a certain proportion range.
Although the present invention has been described in detail hereinabove with general descriptions and specific embodiments, some modifications or improvements can be made on the basis of the present invention, which would be obvious to a person skilled in the art. Therefore, these modifications or improvements made on the basis of the present invention and not departing from the spirit thereof still fall within the scope of the present invention.
Claims (13)
1. A method of treating infection with carbapenem antibiotic-resistant Acinetobacter baumannii, comprising:
administering a therapeutically effective amount of a composition comprising sulbactam and ceftazidime to a subject in need thereof,
wherein the amount of ceftazidime in the composition of sulbactam and ceftazidime is 10%-90% by mass of the amount of sulbactam.
2. The method according to claim 1 , wherein the amount of ceftazidime is 20%-80% of the amount of sulbactam.
3. The method according to claim 1 , wherein the amount of ceftazidime is 20%-40% of the amount of sulbactam.
4. The method according to claim 1 , wherein the carbapenem antibiotic is at least one of meropenem, imipenem, panipenem, biapenem or doripenem.
5. The method according to claim 4 , wherein the carbapenem antibiotic-resistant Acinetobacter baumannii is also resistant to ceftazidime.
6. The method according to claim 1 , wherein the composition of sulbactam and ceftazidime is a non-oral preparation.
7. The method according to claim 6 , wherein the composition of sulbactam and ceftazidime is an injection or an inhalant.
8. The method according to claim 1 , wherein sulbactam and ceftazidime in the composition of sulbactam and ceftazidime are packaged individually or in a mixed manner.
9. The method according to claim 1 , wherein the daily dose of sulbactam in the composition of sulbactam and ceftazidime is 2 g-20 g.
10. The method according to claim 1 , wherein the daily dose of ceftazidime in the composition of sulbactam and ceftazidime is 0.2 g-18 g.
11. The method according to claim 2 , wherein the carbapenem antibiotic is at least one of meropenem, imipenem, panipenem, biapenem or doripenem.
12. The method according to claim 11 , wherein the carbapenem antibiotic-resistant Acinetobacter baumannii is also resistant to ceftazidime.
13. The method according to claim 9 , wherein the daily dose of ceftazidime in the composition of sulbactam and ceftazidime is 0.2 g-18 g.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910162554.4A CN111658642A (en) | 2019-03-05 | 2019-03-05 | Composition for treating carbapenem antibiotic-resistant acinetobacter baumannii infection |
| CN201910162554.4 | 2019-03-05 | ||
| PCT/CN2020/076032 WO2020177546A1 (en) | 2019-03-05 | 2020-02-20 | Composition for treating carbapenem-resistant antibiotic acinetobacter baumannii infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20220175790A1 US20220175790A1 (en) | 2022-06-09 |
| US12194049B2 true US12194049B2 (en) | 2025-01-14 |
Family
ID=72338148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/436,296 Active 2042-04-30 US12194049B2 (en) | 2019-03-05 | 2020-02-20 | Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12194049B2 (en) |
| EP (1) | EP3919059B1 (en) |
| CN (2) | CN111658642A (en) |
| WO (1) | WO2020177546A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024097960A1 (en) * | 2022-11-03 | 2024-05-10 | University Of Kentucky Research Foundation | Compounds with anti- acinetobacter baumannii activity |
| CN116139152A (en) * | 2022-12-15 | 2023-05-23 | 复旦大学附属华山医院 | Composition, medicament and application thereof capable of killing drug-resistant Acinetobacter baumannii |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1214246A (en) | 1998-07-15 | 1999-04-21 | 广州威尔曼药业有限公司 | Composite antiseptic medicine |
| WO2013085152A1 (en) | 2011-12-07 | 2013-06-13 | Union Korea Pharm Co., Ltd. | Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors |
| CN103826639A (en) | 2011-12-07 | 2014-05-28 | 韩国联合制药有限公司 | Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102475703A (en) * | 2010-11-26 | 2012-05-30 | 丽珠医药集团股份有限公司 | Anti-Acinetobacter baumannii drug combination and application thereof |
| LT3221313T (en) * | 2014-11-17 | 2019-03-25 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
| CN107875154B (en) * | 2017-12-25 | 2021-05-14 | 湘北威尔曼制药股份有限公司 | Composition containing piperacillin, pharmaceutical preparation and application thereof |
-
2019
- 2019-03-05 CN CN201910162554.4A patent/CN111658642A/en active Pending
-
2020
- 2020-02-20 CN CN202080011157.8A patent/CN113382734B/en active Active
- 2020-02-20 US US17/436,296 patent/US12194049B2/en active Active
- 2020-02-20 EP EP20766484.8A patent/EP3919059B1/en active Active
- 2020-02-20 WO PCT/CN2020/076032 patent/WO2020177546A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1214246A (en) | 1998-07-15 | 1999-04-21 | 广州威尔曼药业有限公司 | Composite antiseptic medicine |
| WO2013085152A1 (en) | 2011-12-07 | 2013-06-13 | Union Korea Pharm Co., Ltd. | Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors |
| CN103826639A (en) | 2011-12-07 | 2014-05-28 | 韩国联合制药有限公司 | Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| English Translation of Written Opinion issued in corresponding PCT/CN2020/076032 application (2 pages). |
| International Search Report dated May 26, 2020 issued in corresponding PCT/CN2020/076032 application (2 pages). |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3919059A4 (en) | 2022-03-23 |
| CN111658642A (en) | 2020-09-15 |
| EP3919059B1 (en) | 2023-11-01 |
| WO2020177546A1 (en) | 2020-09-10 |
| US20220175790A1 (en) | 2022-06-09 |
| CN113382734B (en) | 2023-07-21 |
| CN113382734A (en) | 2021-09-10 |
| EP3919059A1 (en) | 2021-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7245289B2 (en) | Methods of treating bacterial infections | |
| Ferrara | Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia | |
| KR101737167B1 (en) | Pharmaceutical compositions comprising sulbactam and a beta-lactamase inhibitor | |
| US12194049B2 (en) | Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection | |
| Pechere et al. | Emergence of resistance after therapy with antibiotics used alone or combined in a marine model | |
| KR20190104385A (en) | How to treat a bacterial infection | |
| KR101850265B1 (en) | Compositions comprising antibacterial agent and tazobactam | |
| CN121154634A (en) | Antimicrobial compositions containing avibactam and their uses | |
| US20110166119A1 (en) | Synergistic Combinations of Aztreonam with the Carbapenems Meropenem and Ertapenem | |
| WO2025060701A1 (en) | Antibacterial composition and antibacterial drug | |
| AU2020344214B2 (en) | Antibiotic combination therapies | |
| Bassaris et al. | A randomised, multinational study with sequential therapy comparing ciprofloxacin twice daily and ofloxacin once daily | |
| LeFrock et al. | Cefoxitin therapy in aerobic, anaerobic, and mixed aerobic-anaerobic infections | |
| CN120437135A (en) | Medical use of cedarol in the preparation of Staphylococcus aureus β-lactamase inhibitors | |
| CN116473976A (en) | A kind of purposes of cefepime avibactam | |
| US20160175318A1 (en) | Compositions comprising antibacterial agent and tazobactam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUN, TIANYU;REEL/FRAME:057426/0308 Effective date: 20210823 |
|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |